Glypican-3: a new target for cancer immunotherapy. - Wikidata - awgldk - TriplyDB

Glypican-3: a new target for cancer immunotherapy.

Glypican-3: a new target for cancer immunotherapy.

http://www.wikidata.org/entity/Q34543102

about

Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma Proteoglycans in liver cancer Echographic imaging of tumoral cells through novel nanosystems for image diagnosis.Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin Can serum glypican-3 be a biomarker for effective diagnosis of hepatocellular carcinoma? A meta-analysis of the literature GPC-3 in hepatocellular carcinoma: current perspectives Gene expression profiling of liver cancer stem cells by RNA-sequencing Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: a meta-analysis Can glypican-3 be a disease-specific biomarker?Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma.GPC3 reduces cell proliferation in renal carcinoma cell lines Heparan sulfate proteoglycans and human breast cancer epithelial cell tumorigenicity.Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma.Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis.Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel.CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection.Aptamers against Cells Overexpressing Glypican 3 from Expanded Genetic Systems Combined with Cell Engineering and Laboratory Evolution High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening Clinical correlation of calpain-1 and glypican-3 expression with gallbladder carcinoma.Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma.Epitope mapping by a Wnt-blocking antibody: evidence of the Wnt binding domain in heparan sulfate.Heparan sulfate proteoglycans containing a glypican 5 core and 2-O-sulfo-iduronic acid function as Sonic Hedgehog co-receptors to promote proliferation Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma Glypican-3 antibodies: a new therapeutic target for liver cancer.Therapeutic potential of targeting glypican-3 in hepatocellular carcinoma.A spoonful of sugar makes the melanoma go: the role of heparan sulfate proteoglycans in melanoma metastasis.GPI transamidase and GPI anchored proteins: oncogenes and biomarkers for cancer.Targeting of hepatocellular carcinoma with glypican-3-targeting peptide ligand.Expression profile of altered long non-coding RNAs in patients with HBV-associated hepatocellular carcinoma.A novel miR-219-SMC4-JAK2/Stat3 regulatory pathway in human hepatocellular carcinoma Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3.A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses.Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities.Regulation of TGFβ superfamily signaling by two separable domains of glypican LON-2 in C. elegans.Retinoic acid induced 16 enhances tumorigenesis and serves as a novel tumor marker for hepatocellular carcinoma.Quantification of glypican 3, β-catenin and claudin-1 protein expression in hepatoblastoma and paediatric hepatocellular carcinoma by colour deconvolution.Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy.

P2860

Q26743361-86466568-110F-4E59-B651-3C827A317017 Q26772304-98426F73-1C92-4472-BCE0-5B03A8572D65 Q27012856-97B8DCFD-2774-49CD-BA78-E398632E9E9B Q27015134-1AFF0282-FDC6-454E-AA27-05E74159AC28 Q27023427-14F77A22-7A24-4E8D-9441-DFC5F0350A32 Q28066774-9FF10B1F-5B16-4AE2-A7DF-823CA5185237 Q28483663-1133CD96-42CA-47C6-AA6B-CE09E72C21D2 Q33661257-516BA706-88CC-40DB-99C4-545E3C0326C2 Q33694272-1AFBC06A-B601-4915-B1E4-12552B66AB51 Q33779122-1D48B25E-FE41-48FC-8A52-E8D4107DA4D9 Q33850265-E076612C-7723-4C7F-BFEB-2D473E3983B0 Q33974776-BBD8BE56-12D9-4BCF-A03E-7CAA0C4C2016 Q34169151-52546DE3-FA17-4247-AFE8-539C206F256C Q34475894-390FA6D3-26C9-4BD4-B1D4-586535B2BC67 Q35051445-F66FB7C1-C93C-42D5-8F7F-64035556505A Q35170403-9714D81D-6A38-4CCA-9492-F6A4BB343269 Q35570817-0992D1B6-AA5A-4851-8D32-00434921D6FA Q35957183-A5B48FF0-FE99-400B-BB8B-C085D05AFADD Q36124808-8B5CE1DB-56DB-4843-9AD9-5E652271E46B Q36402695-2F6ACD46-9A5B-4C34-92A4-FB9EB170D776 Q36524756-FE6B4EAF-63DD-40EC-9376-5473D7E7668C Q36712597-C393DE8D-CB14-41C7-ACEC-1750A409BCC4 Q36906823-2614F475-F2C3-425B-BDF8-3F55566A2F06 Q37151121-EB02DB59-6414-4A49-BE54-1F1D598FAA4F Q37282388-520FC8F3-C150-452F-A22A-42FD45996ED7 Q37625736-4240A4CE-9090-4EDA-ACB7-DBB9810B3B20 Q37873514-39639866-17CC-43A6-BC48-11D50139BC80 Q37943014-4D6EEAC9-03AD-485C-9056-A2EEA3785193 Q38131553-691A4722-6CF0-4843-A220-2273216CCB57 Q38331349-132DDFC0-5F87-4A43-909A-4C139F006801 Q38492203-78D86A05-AB1C-4C1F-A416-BB141391190A Q38979570-D15E717A-4034-4AEF-A74C-BB54C6C37722 Q39253341-E0C916C0-F900-4B30-9587-770641D30400 Q39373710-CE1A2963-3A89-43A4-80F2-CEB48AFAFBAC Q41082130-41DA2585-0C1D-4431-896A-4960F6D3BC15 Q42024872-F59DFC17-AEF2-4B0A-8530-CEC6F7277F0C Q42770522-47241D69-50E5-452F-BD5D-6622E41678DC Q45881792-05A16BE3-EFEA-4228-B0C2-24E82C46DF06 Q46405678-89EA67BE-D04B-4FFD-AD29-5E1CE25A23C5 Q47378147-022BEE3C-D344-47B6-8ED5-AF58C86E70D7

P2860

Glypican-3: a new target for cancer immunotherapy.

http://www.wikidata.org/entity/Q34543102

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Glypican-3: a new target for cancer immunotherapy.

@ast

Glypican-3: a new target for cancer immunotherapy.

@en

Glypican-3: a new target for cancer immunotherapy.

@nl

type

label

Glypican-3: a new target for cancer immunotherapy.

@ast

Glypican-3: a new target for cancer immunotherapy.

@en

Glypican-3: a new target for cancer immunotherapy.

@nl

prefLabel

Glypican-3: a new target for cancer immunotherapy.

@ast

Glypican-3: a new target for cancer immunotherapy.

@en

Glypican-3: a new target for cancer immunotherapy.

@nl

P1433

Q34543102-5682F289-7DA2-455A-8124-052F72C083D0

P1476

Q34543102-1537A200-D92D-4A40-B822-362AE12427FD

P2093

Q34543102-0320B87A-7B80-428A-A161-EB19F3CBAE20

Q34543102-BC720072-425F-4464-A48C-37B1A7F28162

P2860

Q34543102-118BCCCF-7B0F-4681-9027-88C59D8C76A4

Q34543102-137433D8-01FE-4D1B-9C35-01299314353F

Q34543102-200BC24E-42B9-4229-93F1-D1CF12A43662

Q34543102-22376A25-4CD9-4A6C-A622-A3DD3367BCF3

Q34543102-24AC728B-5436-42F5-89AE-A54656E44507

Q34543102-2C3B6D3A-D890-4EC1-9A5B-821E6EBBC8AB

Q34543102-321CC8AD-5512-4817-B0A0-EEBB0617C9DC

Q34543102-373E6CFD-88EA-408F-9FD5-1FA7835002E2

Q34543102-3F9D639D-05EF-4EAE-8233-6E4C5B07C7DA

Q34543102-44B9BE60-2FCE-40D1-8BF6-718E0C5279FA

P304

Q34543102-AA00CDCD-404E-4DC6-8F80-954A747EED03

P31

Q34543102-295577d7-02fd-46a8-836b-a865b23ffc6a

Q34543102-F3363C3B-75DB-4DDC-9948-097D84C950E7

P356

Q34543102-6370848A-A0ED-46F2-BDE8-7AC873B1AE2B

P433

Q34543102-FBEC01DF-FB95-4B24-89C9-45C4E78F5208

P478

Q34543102-9E327880-CBFB-4224-840C-1BFFD5712AEA

P577

Q34543102-D6ED8939-2C9B-461B-AB09-3CF37DA3916D

P5875

Q34543102-4C7EC3E7-39C6-4A45-8B90-09AA3D50DC27

P698

Q34543102-5B7D93F9-EE29-42F7-872E-FE44157D72BF

P921

Q34543102-2D85DA85-3B22-4D2F-88C6-660403570A61

P932

Q34543102-8AF877D7-2FC2-4965-8A89-2F1C4096F611

P356

J.EJCA.2010.10.024

P1433

European Journal of Cancer

P1476

Glypican-3: a new target for cancer immunotherapy.

@en

P2093

Heungnam Kim

http://www.w3.org/2001/XMLSchema#string

Mitchell Ho

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome

Glypican-3-deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson-Golabi-Behmel syndrome

Glypicans in growth control and cancer

Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution

Processing by convertases is not required for glypican-3-induced stimulation of hepatocellular carcinoma growth

Characterization of glypican-5 and chromosomal localization of human GPC5, a new member of the glypican gene family

glypican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development

Overgrowth of a mouse model of Simpson-Golabi-Behmel syndrome is partly mediated by Indian hedgehog

The loss of glypican-3 induces alterations in Wnt signaling

Overgrowth of a mouse model of the Simpson-Golabi-Behmel syndrome is independent of IGF signaling

P304

333-338

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EJCA.2010.10.024

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49640615

http://www.w3.org/2001/XMLSchema#string

P698

21112773

http://www.w3.org/2001/XMLSchema#string

P921

P932

3031711

http://www.w3.org/2001/XMLSchema#string